Novo Holdings, along with 30 other investors, has invested in Metagenomi, a biotechnology company that according to Novo Holdings partner Raymond Camahort, has a broad technology that can be used for multiple indications.
With a total of 275 million dollars in fresh capital, Novo Holdings and the other investors have helped extend Metagenomi’s runway and given a boost to the pipeline.
“Part of Novo Holdings’ strategy is to invest in companies that benefit people’s health through science. There are many genetic diseases that are quite devastating and cannot be treated with conventional drugs, such as small molecules. This is where next-generation therapies such as gene therapy and genome editing come into play,” says Novo Ventures partner, Raymond Camahort.
The Oakland, California-based biotechnology company has invented a new technology that can edit the human genome. A DNA strand can be removed, and another can be inserted in its place.
This has so far produced a pipeline of preclinical therapies. One of Metagenomi’s leading disease areas is Hemophilia A, a bleeding disorder.
Metagenomi is still in the preclinical phase, but despite this, it has managed to attract 275 million dollars in a recently completed series B financing round. Initially, Metagenomi raised 175 million dollars, but an expansion secured the company a total of 275 million dollars, with Novo Holdings leading the expansion round for 100 million dollars.
Read more about the story here